†rsrapport Nycomed - Takeda Pharmaceuticals International GmbH

ACCOUNTSCONSOLIDATED ACCOUNTS NOTES7. Financial fixed assetsInvestments Other Otherin associated investments receicompaniesin shares vablesCost beginning of year 6,648 11,302 2,133Additions from acquisition of subsidiaries 0 - 9,681 0Foreign currency conversion effect 0 - 390 0Additions in the year 0 0 11,699Retirements in the year - 6,648 0 0Cost 31.12.00 0 1,231 13,832Value adjustment beginning of year 0 0 0Result before tax 0 0 0Foreign currency conversion effect 0 0 0Value adjustment 31.12.00 0 0 0Book value 31.12.00 0 1,231 13,8328. Prepayments and accrued income2000 1998/99(000)DKK(000)DKKThis item includes unrealised foreign currency losseson loans in foreign currency which serves as hedgingof future cash flow in foreign currency 28,423 32,4699. Shareholder’s equityShareholder’s equity at founding of company 755,680 500Capital increase 31,102 813,544Adjustment of goodwill - 30,279 0Currency effect from conversion of foreignsubsidiaries - 27,856 - 1,295Net result - 43,210 - 57,069Shareholder’s equity 31. December 685,437 755,68010. Long term debtTotal long term debt due more than 5 years after thebalance sheet date 1,691,825 2,037,78311. Deferred incomePayment from partner compensating royalty paymentsfor the years 2001 - 2005 145,232 0–51–